Low expression levels of AR and BAD are associated with decreased overall survival (OS) and relapse-free survival (RFS) in ER+ breast cancer, while their high levels appear to be protective, as Kaplan–Meier survival analyses show (Figure 1D,E). Here, BAD is linked to breast carcinoma.